Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$23.03 USD

23.03
629,434

-0.51 (-2.17%)

Updated May 8, 2024 04:00 PM ET

After-Market: $23.05 +0.02 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Acorda Reports Death in Parkinson's Trials, Stock Down 40%

Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.

    Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus

    Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.

      What's in the Cards for Prothena (PRTA) in Q3 Earnings?

      Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.

        Prothena's Psoriasis Candidate Disappoints in Phase I Study

        Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.

          AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug

          AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.

            Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment

            Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.

              Should You Buy Prothena Corporation PLC (PRTA) Ahead of Earnings?

              Given that Prothena Corporation PLC (PRTA) has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings.

                Can Prothena (PRTA) Deliver a Beat this Earnings Season?

                Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.

                  Prothena (PRTA) Down 5.8% Since Earnings Report: Can It Rebound?

                  Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View

                    Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.

                      What to Expect from Prothena (PRTA) This Earnings Season?

                      Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.

                        Why Is Prothena (PRTA) Up 4.5% Since the Last Earnings Report?

                        Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Prothena (PRTA) Reports Wider-than-Expected Loss in Q4

                          Prothena's wider-than-expected loss in the fourth quarter was disappointing.

                            The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                            The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                              Can Prothena (PRTA) Pull a Surprise This Earnings Season?

                              Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.